Motor Function Measure: validation of a short form (MFM-20) for young children with neuromuscular diseases
Capucine de Lattre, Christine Payan, Carole Vuillerot, Pascal Rippert, Denis de Castro, Carole Bérard, Isabelle Poirot and the MFM-20 Study Group.
Arch Phys Med Rehabil. 2013. 94 : 2218-26.
Validation of MFM version useful in neuromuscular children under 7 years old, the MFM-20. MFM-32 was completed on 194 healthy children aged 2-7 years. Twenty items of the MFM-32 were successfully completed by these children and were used to constitute the MFM-20. 88 children with a neuromuscular disease were rated by the MFM by a trained medical professional. Principal component analysis of the MFM-20 confirmed the 3 functional domains of the MFM (D1, D2 and D3). Inter- and intra-rater reliability of the 3 sub-scores and total score were high (ICC > 0.90) and discriminant validity was good. The MFM-20 can be used as an outcome measure for assessment of motor function in young children with a neuromuscular disease.
Keywords: Neuromuscular disease, Motor function, Disability evaluation, Rehabilitation, Metrology
Articles dans les revues scientifiques
Broadening The Imaging Phenotype of Dysferlinopathy at Different Disease Stages
Díaz J, Woudt L, Suazo L, Garrido C, Caviedes P, Cardenas AM, Castiglioni C, Bevilacqua JA. Muscle Nerve. 2016. 54(2):203-10. The study aimed at describes MRI of dysferlinopathy and to correlate it with objective measures of motor dysfunction.MRI infiltration score...
Myotonic dystrophy type 1: frequency of ophthalmologic findings
Ikeda KS, Iwabe-Marchese C, França MC Jr, Nucci A, Carvalho KM. Arq Neuropsiquiatr. 2016. 74(3):183-8. The purpose of the study was to evaluate the frequency of ophthalmologic abnormalities in a cohort of myotonic dystrophy type 1 (DM1) patients and to correlate them...
Toward an objective measure of functional disability in dysferlinopathy
Woudt L, Di Capua GA, Krahn M, Castiglioni C, Hughes R, Campero M, Trangulao A, González-Hormazábal P, Godoy-Herrera R, Lévy N, Urtizberea JA, Jara L, Bevilacqua JA. Muscle Nerve. 2016. 53(1):49-57. The aim of the study was to assess, clinically and functionally, a...
Computer task performance by subjects with Duchenne muscular dystrophy
Malheiros SR, da Silva TD, Favero FM, de Abreu LC, Fregni F, Ribeiro DC, de Mello Monteiro CB. Neuropsychiatr Dis Treat. 2015. 30;12:41-8. The study aimed at verifying the quantitative performance of people with DMD in undertaking a computer task.An improved...
Diagnostic et histoire naturelle de la dystrophie musculaire de Duchenne
Desguerre I, Laugel V. Arch Pediatr. 2015. 22(12 Suppl 1):12S24-30. Duchenne myopathy is today the most frequently encountered progressive muscular dystrophy in children, with an inexorable, progressive development to death in the third decade. Improvement in survival...
Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype
Servais L, Montus M, Guiner C, Ben Yaou R, Annoussamy M, Moraux A, Hogrel JY, Seferian AM, Zehrouni K, Le Moing AG, Gidaro T, Vanhulle C, Laugel V,Butoianu N, Cuisset JM, Sabouraud P, Cances C, Klein A, Leturcq F, Moullier P, Voit T. Journal of Neuromuscular Diseases....